JMP Securities Reaffirms Market Outperform Rating for Vigil Neuroscience (NASDAQ:VIGL)

Vigil Neuroscience (NASDAQ:VIGL)‘s stock had its “market outperform” rating restated by research analysts at JMP Securities in a research report issued to clients and investors on Thursday, Benzinga reports. They presently have a $23.00 price objective on the stock.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $24.00 price target on shares of Vigil Neuroscience in a report on Wednesday, March 27th.

Vigil Neuroscience Stock Performance

Shares of VIGL traded down $0.03 during midday trading on Thursday, hitting $2.89. 22,124 shares of the company traded hands, compared to its average volume of 100,458. The firm has a 50 day moving average of $3.17 and a 200-day moving average of $4.04. Vigil Neuroscience has a 52 week low of $2.53 and a 52 week high of $11.11. The stock has a market cap of $106.58 million, a price-to-earnings ratio of -1.35 and a beta of 1.77.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. lifted its holdings in shares of Vigil Neuroscience by 0.7% in the 4th quarter. Vanguard Group Inc. now owns 799,197 shares of the company’s stock valued at $2,701,000 after acquiring an additional 5,231 shares during the last quarter. Barclays PLC raised its position in Vigil Neuroscience by 18.4% in the 4th quarter. Barclays PLC now owns 123,795 shares of the company’s stock worth $419,000 after purchasing an additional 19,205 shares during the period. Sphera Funds Management LTD. purchased a new stake in Vigil Neuroscience in the 4th quarter worth about $1,809,000. Bridgeway Capital Management LLC purchased a new stake in Vigil Neuroscience in the 4th quarter worth about $449,000. Finally, PEAK6 Investments LLC raised its position in Vigil Neuroscience by 74.3% in the 4th quarter. PEAK6 Investments LLC now owns 41,486 shares of the company’s stock worth $140,000 after purchasing an additional 17,690 shares during the period. Institutional investors own 83.64% of the company’s stock.

About Vigil Neuroscience

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.